

DAFTAR PUSTAKA

- Abbas, T. and Dutta, A., 2009. p21 in cancer: intricate networks and multiple activities. *Nature Reviews Cancer*. 9(6): 400-414.
- Asafudullah, S.M., Salam, M.A., & Badruddoza, S.M., 2011. Evaluation of diagnostic accuracy of different biomarkers for prostate cancer. *Pakistan J. Med. Sci.* 27: 48–51. doi:10.12669/pjms.271.808
- Balk, S.P. and Knudsen, K.E., 2008. AR, the cell cycle, and prostate cancer. *Nuclear receptor signaling*. 6(1): 06001.
- Bashir, M.N., 2015. MINI-REVIEW Epidemiology of Prostate Cancer . 16: 5137-41.
- Boss, M.K., Bristow, R. and Dewhirst, M.W., 2014. Linking the history of radiation biology to the hallmarks of cancer. *Radiation research*. 181(6): 561-577.
- Boykevisch, S., Zhao, C., Sondermann, H., Philippidou, P., Halegoua, S., Kuriyan, J. and Bar-Sagi, D., 2006. Regulation of ras signaling dynamics by Sos-mediated positive feedback. *Current biology*. 16(21): 2173-2179.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*. 68(6): 394-424.
- Chardin, P. and Mattei, M.G., 1994. Chromosomal localization of two genes encoding human ras exchange factors: SOS1 maps to the 2p22→ p16 region and SOS2 to the 14q21→ q22 region of the human genome. *Cytogenetic and Genome Research*. 66(1): 68-69.
- Chen, W.Y., Tsai, Y.C., Siu, M.K., Yeh, H.L., Chen, C.L., Yin, J.J., Huang, J. and Liu, Y.N., 2017. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. *Oncogene*. 36(45): 6213-6224.
- Cheng, L., Sun, X., Scicluna, B.J., Coleman, B.M. and Hill, A.F., 2014. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. *Kidney international*. 86(2): 433-444.
- Coppin, L., Leclerc, J., Vincent, A., Porchet, N. and Pigny, P., 2018. Messenger RNA Life-cycle in cancer cells: emerging role of conventional and non-conventional RNA-binding proteins?. *International journal of molecular sciences*. 19(3): 650.
- Davey, R.A. and Grossmann, M., 2016. Androgen receptor structure, function and biology: from bench to bedside. *The Clinical Biochemist Reviews*, 37(1), p.3.
- Eastman, A., 2004. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. *Journal of cellular biochemistry*. 91(2): 223-231.
- Fernández-Medarde, A. and Santos, E., 2011. Ras in cancer and developmental diseases. *Genes & cancer*. 2(3): 344-358.
- Fizazi, K., Martinez, L.A., Sikes, C.R., Johnston, D.A., Stephens, L.C., McDonnell, T.J., Logothetis, C.J., Trapman, J., Pisters, L.L., Ordoñez, N.G. and Troncoso,

- P., 2002. The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer. *Clinical cancer research*. 8(3): 775-781.
- Gandaglia, G., Abdollah, F., Schiffmann, J., Trudeau, V., Shariat, S.F., Kim, S.P., et al., 2014. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate* 74: 210–216. doi:10.1002/pros.22742
- Gelmann, E.P., 2002. Molecular biology of the androgen receptor. *Journal of Clinical Oncology*. 20(13): 3001-3015.
- Gordetsky, J. and Epstein, J., 2016. Grading of prostatic adenocarcinoma: current state and prognostic implications. *Diagnostic pathology*. 11(1): 25.
- Graham, L. and Schweizer, M.T., 2016. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. *Medical oncology*. 33(5): 44.
- Gurumurthy, D., 2015. Prostate carcinoma: correlation of histopathology with serum prostate specific antigen. *Sci. J. Clin. Med.* 4: 1. doi:10.11648/j.sjcm.s.2015040401.11
- Hanahan, D. and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. *Cell*. 144(5): 646-674.
- Hessvik, N.P., Sandvig, K., Llorente, A., 2013. Exosomal miRNAs as biomarkers for prostate cancer. *Front. Genet.* 4: 1–9.
- Inoue, T. and Ogawa, O., 2011. Role of signaling transduction pathways in development of castration-resistant prostate cancer. *Prostate Cancer*. 2011.
- Iversen, L., Tu, H.L., Lin, W.C., Christensen, S.M., Abel, S.M., Iwig, J., Wu, H.J., Gureasko, J., Rhodes, C., Petit, R.S. and Hansen, S.D., 2014. Ras activation by SOS: Allosteric regulation by altered fluctuation dynamics. *Science*. 345(6192): 50-54.
- Jain, A.K., Raina, K., & Agarwal, R., 2013. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model. *Cell Cycle* 12: 1598–1604. doi:10.4161/cc.24741
- Jayapradeep, D.P., Prakash, V.B., Philipose, T.R., & Pai, M.R., 2017. Histomorphologic Correlation of PSA Levels in Prostatic Pathology. *Natl. J. Lab. Med.* 6: 28–32. doi:10.7860/NJLM/2017/30113
- Jorge, R., Zarich, N., Oliva, J.L., Azañedo, M., Martínez, N., de la Cruz, X. and Rojas, J.M., 2002. HSos1 contains a new amino-terminal regulatory motif with specific binding affinity for its pleckstrin homology domain. *Journal of Biological Chemistry*. 277(46): 44171-44179.
- Kanwal, S., 2013. *Effect of O-GlcNAcylation on tamoxifen sensitivity in breast cancer derived MCF-7 cells* (Doctoral dissertation, Paris 5).
- Karimian, A., Ahmadi, Y. and Yousefi, B., 2016. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. *DNA repair*. 42: 63-71.
- Kementrian Kesehatan Republik Indonesia, 2015. Karsinoma Prostat. Pandu. Penatalaksanaan Karsinoma Prostat 47.

- Khant, V., Goswami, H., & Shah, P., 2017. Correlation of serum prostate-specific antigen level in various prostate pathology in elderly men. *Int. J. Med. Sci. Public Heal.* 6: 1. doi:10.5455/ijmsph.2017.17072016588
- Knudsen, K.E. and Penning, T.M., 2010. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. *Trends in Endocrinology & Metabolism.* 21(5): 315-324.
- Koryakina, Y., Knudsen, K.E. and Gioeli, D., 2015. Cell-cycle-dependent regulation of androgen receptor function. *Endocrine-related cancer.*22(2): 249-264.
- Lacombe, L., Maillette, A., Meyer, F., Veilleux, C., Moore, L., & Fradet, Y., 2001. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. *Int. J. Cancer* 95: 135–139. doi:10.1002/1097-0215(20010520)95:3<135::AID-IJC1023>3.0.CO;2-3
- Lee, E.W., Lee, M.S., Camus, S., Ghim, J., Yang, M.R., Oh, W., Ha, N.C., Lane, D.P. and Song, J., 2009. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. *The EMBO journal.* 28(14): 2100-2113.
- Lonergan, P.E. and Tindall, D.J., 2011. Androgen receptor signaling in prostate cancer development and progression. *Journal of carcinogenesis.* 10
- Malumbres, M. and Barbacid, M., 2009. Cell cycle, CDKs and cancer: a changing paradigm. *Nature reviews cancer.* 9(3): 153-166.
- Margarit, S.M., Sondermann, H., Hall, B.E., Nagar, B., Hoelz, A., Pirruccello, M., Bar-Sagi, D. and Kuriyan, J., 2003. Structural evidence for feedback activation by Ras· GTP of the Ras-specific nucleotide exchange factor SOS. *Cell.* 112(5): 685-695.
- Marlowe, J.L. and Puga, A., 2005. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. *Journal of cellular biochemistry.* 96(6): 1174-1184.
- Nimnual, A. and Bar-Sagi, D., 2002. The two hats of SOS. *Science Signaling,* 2002(145): pe36-pe36.
- Omar, E.A., Behlouli, H., Chevalier, S., & Aprikian, A.G., 2001. Relationship of p21WAF-1 protein expression with prognosis in advanced prostate cancer treated by androgen ablation. *Prostate* 49: 191–199. doi:10.1002/pros.1134
- Pan, J., Ding, M., Xu, K., Yang, C. and Mao, L.J., 2017. Exosomes in diagnosis and therapy of prostate cancer. *Oncotarget.* 8(57): 97693.
- Papatsoris, A.G., Karamouzis, M. V., & Papavassiliou, A.G., 2007. The power and promise of “rewiring” the mitogen-activated protein kinase network in prostate cancer therapeutics. *Mol. Cancer Ther.* 6: 811–819. doi:10.1158/1535-7163.MCT-06-0610
- Pierre, S. and Coumoul, X., 2011. Understanding SOS (son of sevenless). *Biochemical pharmacology.* 82(9): 1049-1056.
- Ramalingam, S., Ramamurthy, V.P. and Njar, V.C., 2017. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and

- novel therapeutic targets. *The Journal of Steroid Biochemistry and Molecular Biology*. 166: 16-27.
- Reams, R.R., Jones-Triche, J., Chan, O.T.M., Hernandez, B.Y., Soliman, K.F.A., & Yates, C., 2015. Immunohistological analysis of ABCD3 expression in Caucasian and African American prostate tumors. *Biomed Res. Int.* 2015. doi:10.1155/2015/132981
- Rigaud, J., Tiguert, R., Decobert, M., Hovington, H., Latulippe, E., Laverdiere, J., et al., 2004. Expression of p21 Cell Cycle Protein Is An Independent Predictor of Response to Salvage Radiotherapy after Radical Prostatectomy. *Prostate* 58: 269–276. doi:10.1002/pros.10329
- Rodríguez, Z.J., & O’Kennedy, R., 2017. New Approaches For The Development Of Diagnostic Systems For Prostate Cancer. *Asian Hosp. Healthc. Manag.* 18–23.
- Romics, I., Bánfi, G., Székely, E., Krenács, T. and Szende, B., 2008. Expression of p21 waf1/cip1, p27 kip1, p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer. *Pathology & Oncology Research*. 14(3): 307-311.
- Roninson, I.B., 2003. Tumor cell senescence in cancer treatment. *Cancer Res.* 63: 2705–2715.
- Schiewer, M.J., Augello, M.A. and Knudsen, K.E., 2012. The AR dependent cell cycle: mechanisms and cancer relevance. *Mol Cell Endocrinol.* 352(1-2): 34-45.
- Shand, R.L. and Gelmann, E.P., 2006. Molecular biology of prostate-cancer pathogenesis. *Current opinion in urology*. 16(3): 123-131.
- Signoretti, S., Waltregny, D., Dilks, J., Isaac, B., Lin, D., Garraway, L., et al., 2000. P63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development. *Am. J. Pathol.* 157: 1769–1775. doi:10.1016/S0002-9440(10)64814-6
- Sondermann, H., Nagar, B., Bar-Sagi, D. and Kuriyan, J., 2005. Computational docking and solution x-ray scattering predict a membrane-interacting role for the histone domain of the Ras activator son of sevenless. *Proceedings of the National Academy of Sciences*. 102(46): 16632-16637.
- Street, J.M., Koritzinsky, E.H., Glispie, D.M., Star, R.A., & Yuen, P.S., 2017. Urine Exosomes: An Emerging Trove of Biomarkers. *Adv Clin Chem.* 78(1):103-122.
- Sturgeon, C.M., Duffy, M.J., Stenman, U.H., Lilja, H., Brünner, N., Chan, D.W., et al., 2008. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. *Clin. Chem.* 54. doi:10.1373/clinchem.2008.105601
- Théry, C., Zitvogel, L. and Amigorena, S., 2002. Exosomes: composition, biogenesis and function. *Nature reviews immunology*. 2(8): 569-579.
- Timofeeva, O.A., Zhang, X., Ransom, H.W., Varghese, R.S., Kallakury, B.V.S., Wang, K., et al., 2009. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. *Int. J. Oncol.* 35: 751–760. doi:10.3892/ijo-00000388

- Turley, R.S., Hamilton, R.J., Terris, M.K., Kane, C.J., Aronson, W.J., Presti, J.C., Amling, C.L., Freedland, S.J. and SEARCH Database Study Group, 2008. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. *The Journal of urology*. 179(2): 523-528.
- Umbas, R., Mochtar, C.A. and Rahardjo, H., 2011. Current status of prostate cancer in Asia. *Indonesian Journal of Cancer*. 5(1).
- Wong, M.C.S., Goggins, W.B., Wang, H.H.X., Fung, F.D.H., Leung, C., Wong, S.Y.S., et al. 2016. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. *Eur. Urol*. 70: 862–74.
- Yang, V.W., 2018. The cell cycle. In *Physiology of the Gastrointestinal Tract* (pp. 197-219). Academic Press.
- Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J. and Mi, S., 2015. Exosome and exosomal microRNA: trafficking, sorting, and function. *Genomics, proteomics & bioinformatics*. 13(1): 7-24.